Sandoz Group AG
Forum 1
Novartis Campus
Basel 4056
Switzerland
41 61 324 11 11
https://www.sandoz.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 22,633
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Richard Saynor | Chief Executive Officer | 無 | 無 | 1967 |
| Mr. Colin Michael Bond | Chief Financial Officer | 無 | 無 | 1960 |
| Mr. Asaf Gal | Chief Technology Officer | 無 | 無 | 1969 |
| Ms. Claire D'Abreu-Hayling | Chief Scientific Officer | 無 | 無 | 1964 |
| Ms. Karen M. King | Head Global Investor Relations | 無 | 無 | 無 |
| Ms. Ingrid Sollerer | General Counsel & Chief Compliance Officer | 無 | 無 | 1974 |
| Ms. Tripti Jha | Chief People Officer | 無 | 無 | 1977 |
| Mr. Francisco Ballester | President of International | 無 | 無 | 1961 |
| Mr. Pierre Bourdage | Chief Commercial Officer | 無 | 無 | 1979 |
| Dr. Glenn A. Gerecke Ph.D. | Chief Manufacturing & Supply Officer | 無 | 無 | 1959 |
截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
公司管治
截至 2024年6月1日 止，Sandoz Group AG 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中：6；董事會：4；股東權利：9；現金賠償：2。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
